Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s stock price traded up 11.8% during trading on Thursday . The company traded as high as C$1.93 and last traded at C$1.89. 95,604 shares traded hands during trading, an increase of 2% from the average session volume of 93,508 shares. The stock had previously closed at C$1.69.
Medicenna Therapeutics Trading Up 14.2 %
The company has a quick ratio of 4.65, a current ratio of 5.00 and a debt-to-equity ratio of 0.06. The business’s fifty day moving average is C$0.97 and its 200 day moving average is C$0.61. The firm has a market capitalization of C$134.41 million, a price-to-earnings ratio of -7.33 and a beta of 1.16.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Recommended Stories
- Five stocks we like better than Medicenna Therapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- Disney Stock Catches 3 Upgrades In a Single Week
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
- What is the Hang Seng index?
- Delta Airline’s Put Option Activity Isn’t Bad News
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
